The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43.
Melody A. Cobleigh
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Stewart J. Anderson
No relevant relationships to disclose
Thomas B. Julian
No relevant relationships to disclose
Kalliopi P. Siziopikou
No relevant relationships to disclose
Douglas W. Arthur
No relevant relationships to disclose
Rachel Rabinovitch
No relevant relationships to disclose
Ping Zheng
No relevant relationships to disclose
Eleftherios P Mamounas
No relevant relationships to disclose
Alice Marie Luknic
No relevant relationships to disclose
Robert J. Behrens
No relevant relationships to disclose
Luis Chu
Stock Ownership - Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis; Roche/Genentech; Sanofi
Research Funding - Roche
Nick C. Leasure
No relevant relationships to disclose
James Norman Atkins
No relevant relationships to disclose
Jonathan Polikoff
No relevant relationships to disclose
Thomas E. Seay
No relevant relationships to disclose
R Dirk Noyes
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
Worta J. McCaskill-Stevens
No relevant relationships to disclose
Norman Wolmark
No relevant relationships to disclose